The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Glial Promoter Selectivity following AAV-Delivery to the Immature Brain
Open accessAbstract
Recombinant adeno-associated virus (AAV) vectors are versatile tools for gene transfer to the central nervous system (CNS) and proof-of-concept studies in adult rodents have shown that the use of cell type-specific promoters is sufficient to target AAV-mediated transgene expression to glia. However, neurological disorders caused by glial pathology usually have an early onset. Therefore, modelling and treatment of these conditions require expanding the concept of targeted glial transgene expression by promoter selectivity for gene delivery to the immature CNS. Here, we have investigated the AAV-mediated green fluorescent protein (GFP) expression driven by the myelin basic protein (MBP) or glial fibrillary acidic protein (GFAP) promoters in the developing mouse brain. Generally, the extent of transgene expression after infusion at immature stages was widespread and higher than in adults. The GFAP promoter-driven GFP expression was found to be highly specific for astrocytes following vector infusion to the brain of neonates and adults. In contrast, the selectivity of the MBP promoter for oligodendrocytes was poor following neonatal AAV delivery, but excellent after vector injection at postnatal day 10. To extend these findings obtained in naïve mice to a disease model, we performed P10 infusions of AAV-MBP-GFP in aspartoacylase (ASPA)-deficient mouse mutants presenting with early onset oligodendrocyte pathology. Spread of GFP expression and selectivity for oligodendrocytes in ASPA-mutants was comparable with our observations in normal animals. Our data suggest that direct AAV infusion to the developing postnatal brain, utilising cellular promoters, results in targeted and long-term transgene expression in glia. This approach will be relevant for disease modelling and gene therapy for the treatment of glial pathology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“While the Mbp promoter holds promise for potential clinical applications, its murine origin, relative big size and poor specificity following neonatal vector delivery, are potential caveats (von Jonquieres et al., 2013).”
From Recombinant Human Myelin-Associated Glycoprotein Promoter Drives Selective AAV-Mediated Transgene Expression in Oligodendrocytes (2016) · cites this paper as von Jonquieres et al., 2013
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“To date, the only cellular promoter used for AAV-mediated transgene expression in oligodendrocytes is the murine 1.9 kb Mbp cis-regulating element and a truncated version spanning the proximal 1.3 kb upstream region including parts of Mbp exon 1 (Chen et al., 1998; Lawlor et al., 2009; von Jonquieres et al., 2013).”
From Recombinant Human Myelin-Associated Glycoprotein Promoter Drives Selective AAV-Mediated Transgene Expression in Oligodendrocytes (2016) · cites this paper as von Jonquieres et al., 2013
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Preclinical proof-of-concept studies showing successful modification of the AAV system towards selective transgene expression in oligodendrocytes used “neurotropic” serotypes but employed the promoter of the mouse myelin basic protein (Mbp) gene (Chen et al., 1998; Lawlor et al., 2009; von Jonquieres et al., 2013).”
From Recombinant Human Myelin-Associated Glycoprotein Promoter Drives Selective AAV-Mediated Transgene Expression in Oligodendrocytes (2016) · cites this paper as von Jonquieres et al., 2013
The cited source says what the claim attributes to it.
In the citing paper
“Although a comparison between the transduction profiles of the vectors carrying the MAG promoter (this study) and the Mbp promoter (von Jonquieres et al., 2013) is not feasible, it appears that in neonates the MAG promoter might be better suited for transgene expression targeted to oligodendrocytes (90%) than the Mbp promoter (25%).”
From Recombinant Human Myelin-Associated Glycoprotein Promoter Drives Selective AAV-Mediated Transgene Expression in Oligodendrocytes (2016) · cites this paper as von Jonquieres et al., 2013
The cited source says what the claim attributes to it.
In the citing paper
“We have shown previously that the vector spread depends on the developmental stage of the target tissue at the time of infusion but not on the cellular promoter used in the expression cassette (von Jonquieres et al., 2013).”
From Recombinant Human Myelin-Associated Glycoprotein Promoter Drives Selective AAV-Mediated Transgene Expression in Oligodendrocytes (2016) · cites this paper as von Jonquieres et al., 2013
The cited source says what the claim attributes to it.
In the citing paper
“Moreover, we have previously reported a largely superior vector spread following neonatal compared with adult AAV delivery to the CNS (von Jonquieres et al., 2013).”
From Recombinant Human Myelin-Associated Glycoprotein Promoter Drives Selective AAV-Mediated Transgene Expression in Oligodendrocytes (2016) · cites this paper as von Jonquieres et al., 2013
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cahoy, J. D., Emery, B., Kaushal, A., Foo, L. C., Zamanian, J. L., Christopherson, K. S., Xing, Y., Lubischer, J. L., Krieg, P. A., Krupenko, S. A., et al. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.4178-07.2008 · Cited by 3,129
Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes
Foust, K. D., Nurre, E., Montgomery, C. L., Hernandez, A., Chan, C. M., & Kaspar, B. K. (2009) · Nature Biotechnology · doi:10.1038/nbt.1515 · Cited by 1,456 · cited 15×
“This developmental stage of the mouse CNS translates to the start of the last prenatal trimester in humans [32].”
BackgroundInfluentialTranslating developmental time across mammalian species
Clancy, B., Darlington, R. B., & Finlay, B. L. (2001) · Neuroscience · doi:10.1016/s0306-4522(01)00171-3 · Cited by 1,221
Quantitative analysis of the packaging capacity of recombinant adeno-associated virus
Dong, J.-Y., Fan, P.-D., & Frizzell, R. A. (1996) · Human Gene Therapy · doi:10.1089/hum.1996.7.17-2101 · Cited by 583
Gray, S. J., Matagne, V., Bachaboina, L., Yadav, S., Ojeda, S. R., & Samulski, R. J. (2011) · Molecular Therapy · doi:10.1038/mt.2011.72 · Cited by 501
Comparative Analysis of Adeno-Associated Viral Vector Serotypes 1, 2, 5, 7, And 8 in Mouse Brain
Taymans, J.-M., Vandenberghe, L. H., Haute, C. V. D., Thiry, I., Deroose, C. M., Mortelmans, L., Wilson, J. M., Debyser, Z., & Baekelandt, V. (2007) · Human Gene Therapy · doi:10.1089/hum.2006.178 · Cited by 305
Zhang, H., Yang, B., Mu, X., Ahmed, S. S., Su, Q., He, R., Wang, H., Mueller, C., Sena-Esteves, M., Brown, R., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2011.98 · Cited by 291
Klein, R. L., Meyer, E. M., Peel, A. L., Zolotukhin, S., Meyers, C., Muzyczka, N., & King, M. A. (1998) · Experimental Neurology · doi:10.1006/exnr.1997.6736 · Cited by 252
Recent developments in adeno‐associated virus vector technology
Büning, H., Perabò, L., Coutelle, O., Quadt‐Humme, S., & Hallek, M. J. (2008) · The Journal of Gene Medicine · doi:10.1002/jgm.1205 · Cited by 204
Klugmann, M., Symes, C. W., Leichtlein, C. B., Klaussner, B. K., Dunning, J., Fong, D. M., Young, D., & During, M. J. (2004) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2004.10.002 · Cited by 198
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Items 101–133 of 133
Peelaerts, W., Brito, F., den Haute, C. V., Janer, A. B., Steiner, J. A., Brundin, P., & Baekelandt, V. (2021) · Human Gene Therapy · doi:10.1089/hum.2021.012 · Cited by 7
Zhong, J., Gunner, G., Henninger, N., Schafer, D. P., & Bosco, D. A. (2023) · Journal of Visualized Experiments · doi:10.3791/64701 · Cited by 5
Sehara, Y., Hayashi, Y., Ohba, K., Uchibori, R., Urabe, M., Inutsuka, A., Shimazaki, K., Kawai, K., & Mizukami, H. (2021) · Human Gene Therapy · doi:10.1089/hum.2021.106 · Cited by 6
Chen, S., He, B., Singh, S., & Martin, N. P. (2023) · Neuromethods · doi:10.1007/978-1-0716-2918-5_6 · Cited by 4
FOXG1 Improves Cognitive Function in Alzheimer's Disease by Promoting Endogenous Neurogenesis
Pan, W., Xu, L., Wang, Y., Wang, Y., Wang, J., Qian, X., Zhou, C., Wang, H. X., Fan, X., & Wang, J. (2025) · The FASEB Journal · doi:10.1096/fj.202403299rr · Cited by 5
MECP2 impairs neuronal structure by regulating KIBRA
Williams, A. A., White, R., Siniard, A. L., Corneveaux, J. J., Huentelman, M. J., & Duch, C. (2016) · Neurobiology of Disease · doi:10.1016/j.nbd.2016.03.019 · Cited by 4
Developing a minimally invasive gene therapy for multiple sclerosis
Nijhuis, P. J. H., Romijn, M., Honing, R., van Zon, G., Huitinga, I., de Winter, F., & Verhaagen, J. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101504 · Cited by 2
Alexander Disease and Astrotherapeutics
Brenner, M., & Messing, A. (2014) · Springer eBooks · doi:10.1007/978-1-4939-0974-2_5 · Cited by 3
Hay, C. M., Jackson, S., Mitew, S., Scott, D. J., Koenning, M., Bensen, A. L., Bujalka, H., Kilpatrick, T. J., & Emery, B. (2021) · Neural Development · doi:10.1186/s13064-021-00156-y · Cited by 3
Oligodendrocytes, the Forgotten Target of Gene Therapy
Ozgür-Gunes, Y., Stunff, C. L., & Bougneres, P. F. (2024) · Cells · doi:10.3390/cells13231973 · Cited by 4
Lutz, B. (2014) · Wiley eBooks · doi:10.1002/9781118451281.ch4 · Cited by 3
Self-citationGene Therapy in Crohn’s Disease: Current Preclinical Challenges and Future Translational Avenues
Abdalla, S., Brouquet, A., Badin, R. A., & Bougneres, P. F. (2025) · Biomedicines · doi:10.3390/biomedicines13123078 · Cited by 2
Degenerative Disorders of the Newborn
Elitt, C. M., & Volpe, J. J. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-42876-7.00029-6 · Cited by 2
Gene therapy for Krabbe disease: evidence from mouse and canine models
Li, Y., Dong, X., Guo, J. C., & Lv, Y. (2025) · Gene · doi:10.1016/j.gene.2025.149949 · Cited by 1
Oudart, M., van Loo, K. M. J., & Kronenberg‐Versteeg, D. (2026) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2026.1777650 · Cited by 1
Specific Expression of Foreign Gene in Postnatal Mouse Glial Cells using Electroporation
Ding, X., Hu, Z., Zhao, Y., Gu, X., Yan, R., Wu, L., Huang, X., Liu, S., Wu, Y., Zhao, T., et al. (2013) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12212 · Cited by 1
(2014) · Human Gene Therapy Clinical Development · doi:10.1089/humc.2014.2509 · Cited by 1
Degenerative Disorders of the Newborn
Elitt, C. M., & Volpe, J. J. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-10513-5.00033-4 · Cited by 1
Chemical Modulation of AAV Trafficking
Berry, G. E. (2016) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/dpe3-gy73
Arvanian, V. L., & Petrosyan, H. A. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-809813-4.00015-6
Editorial: Gene therapy for the central and peripheral nervous system, volume II
Tosolini, A. P., & Smith, G. M. (2023) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2023.1258458
AAV gene therapy for Cockayne syndromePreprint
Batista, A. R., Scholand, A. C., Callahan, W. S., Watson, M. K., Sion, C. M., Mola, T., O’Hara, K., King, O. D., King, R. M., & Sena‐Esteves, M. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.06.06.658349
Baronio, D., Stevenson, T. J., Demmitt-Rice, C. E., Nuebel, E., Blackwell, A. M., & Bonkowsky, J. L. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.10.14.682039
Khalil, M., Bisignani, M., & Kandler, K. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2025.12.03.692215
Rodriguez, A. G. (2016) · theses.fr (ABES) · doi:10.70675/ecd0f3cbz19d7z406bza88eze6d1c4e9be0e
Modélisation et recherche de stratégies expérimentales dans l’atrophie multisystématisée
Guerin, P. A. (2018) · theses.fr (ABES) · doi:10.70675/b4a315bfz31baz46d1z9e9fz88481e022180
Roles of astroglial cannabinoid type 1 receptors (CB1) in memory and synaptic plasticity
Robin, L. M. (2018) · theses.fr (ABES) · doi:10.70675/1fd1dda8z3f4bz404azbdf6z5b648e4c4053
Preclinical gene therapy using recombinant AAV vectors in mouse models of two human diseases
Günes, Y. Ö. (2022) · theses.fr (ABES) · doi:10.70675/52c9a808z1652z42c4zae82zc812b95f1723
AAV-mediated gene therapy demonstrates phenotypic rescue in a mouse model of Cockayne syndrome
Batista, A. R., Scholand, A. C., Callahan, W. S., Watson, M. K., Sion, C. M., Mola, T., O'Hara, K., Wentworth, S. A., Sena-Esteves, W. S., King, O. D., et al. (2026) · Journal of Clinical Investigation · doi:10.1172/jci196689
Suk, K. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.118407
Chan, K. Y., Lin, C.-Y., Huang, Q., Pacouret, S., Zheng, Q., Harvey, J. W., Brauer, P. P., Johnston, J., Serack, F. E., Davis, J. R., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.09.23.753669
Khalil, M., Bisignani, M., & Kandler, K. (2026) · Frontiers in Genome Editing · doi:10.3389/fgeed.2026.1946992
Metadata
- Authors
- von Jonquieres, G., Mersmann, N., Klugmann, C. B., Harasta, A. E., Lutz, B., Teahan, O., Housley, G. D., Fröhlich, D., Krämer-Albers, E.-M., & Klugmann, M.
- Affiliations
- Johannes Gutenberg University Mainz (DE)
- UNSW Sydney (AU)
- Corresponding author
- Klugmann, Matthias
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2013-06-14
- Volume
- 8
- Issue
- 6
- Pages
- e65646
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3683058
- OpenAlex
- W2009016214
- Cited by
- 133
- References
- 33
- Citations by year
- 2026: 5 · 2025: 10 · 2024: 6 · 2023: 8 · 2022: 7 · 2021: 14 · 2020: 9 · 2019: 13 · 2018: 11 · 2017: 12 · 2016: 13 · 2015: 9 · 2014: 13 · 2013: 3
- FWCI
- 8.40
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- Association Européenne contre les Leucodystrophies
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
- Keywords
- adeno-associated virus vectors, myelin basic protein promoter, glial fibrillary acidic protein promoter, astrocytes, oligodendrocytes, neonatal brain development, postnatal brain, aspartoacylase deficiency, lysosomal storage disease, glial pathology, AAV gene therapy, GFP expression
- MeSH terms
- Dependovirus, Age Factors, Animals, Animals, Newborn, Astrocytes, Brain, Cells, Cultured, Myelin Basic Protein, Genetic Vectors, Glial Fibrillary Acidic Protein, Mice, Inbred C57BL, Oligodendroglia, Organ Specificity, Promoter Regions, Genetic, Genetic Therapy, Gene Expression, Canavan Disease, Transgenes, Green Fluorescent Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
